US$ 21.95
glp 1 agonist osteoporosis GLP-1s and Bone Health: What the Evidence Says About Semaglutide, Bone Density, and Muscle Loss The Beneficial Effects of GLP-1
Description
The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models
Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication

However, genetic variants can alter the response in some.
But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

This article explores current clinical evidence, provider decision-making frameworks, and how genetic insights may inform a personalized conversation with your healthcare